<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3433">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783311</url>
  </required_header>
  <id_info>
    <org_study_id>EuSNAP_COV101</org_study_id>
    <nct_id>NCT04783311</nct_id>
  </id_info>
  <brief_title>Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults</brief_title>
  <official_title>A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a&#xD;
      recombinant protein vaccine, for the prevention of COVID-19 in healthy adults&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate AEs</measure>
    <time_frame>within 30 minutes after each IP dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited local and systemic AEs</measure>
    <time_frame>for 7 days after each IP dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited AEs</measure>
    <time_frame>within 28 days after the last IP dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs</measure>
    <time_frame>within 52 weeks after the last IP dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AESIs</measure>
    <time_frame>within 52 weeks after the last IP dosing</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Phase 1 - EuCorVac-19 Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - EuCorVac-19 High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - EuCorVac-19 Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - EuCorVac-19 High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Placebo comparator group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EuCorVac-19</intervention_name>
    <description>Two intramuscular doses (0.5mL per dose) at 3-week interval</description>
    <arm_group_label>Phase 1 - EuCorVac-19 High dose group</arm_group_label>
    <arm_group_label>Phase 1 - EuCorVac-19 Low dose group</arm_group_label>
    <arm_group_label>Phase 2 - EuCorVac-19 High dose group</arm_group_label>
    <arm_group_label>Phase 2 - EuCorVac-19 Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Two intramuscular doses (0.5mL per dose) at 3-week interval</description>
    <arm_group_label>Phase 1 - EuCorVac-19 High dose group</arm_group_label>
    <arm_group_label>Phase 1 - EuCorVac-19 Low dose group</arm_group_label>
    <arm_group_label>Phase 2 - Placebo comparator group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals who voluntarily decide to participate in this study and provide written&#xD;
             informed consent&#xD;
&#xD;
               -  Healthy male and female adult at the age of 19 to 50 years (Part A)&#xD;
&#xD;
               -  Healthy male and female adult at the age of 19 to 75 years (Part B)&#xD;
&#xD;
          2. Individuals who are available for all visit procedures including telephone visits&#xD;
             during the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. COVID-19 positive based on RT-PCR using upper respiratory tract or lower respiratory&#xD;
             tract sampling or COVID-19 antibody positive&#xD;
&#xD;
          2. History of SARS-CoV, MERS-CoV or SARS-CoV-2 infection&#xD;
&#xD;
          3. History of vaccination against SARS-CoV, MERS-CoV or SARS-CoV-2&#xD;
&#xD;
          4. Immune system disorders including immunodeficiency disease&#xD;
&#xD;
          5. Clinically significant abnormalities in clinical laboratory test, ECGs and chest X-ray&#xD;
             during screening in the opinion of the investigator&#xD;
&#xD;
          6. Fever within 3 days prior to screening or serious acute or chronic infection within 7&#xD;
             days prior to screening requiring systemic antibiotics or antivirals&#xD;
&#xD;
          7. Evidence or history of serious acute, chronic, or progressive disease which, in the&#xD;
             opinion of the investigator, makes the individual ineligible for the study&#xD;
&#xD;
          8. History of severe allergic reactions or severe hypersensitivity reactions to the IP or&#xD;
             any of its components&#xD;
&#xD;
          9. History of therapy that might affect immunity: treatment with immunosuppresants or&#xD;
             immune modifying drugs, anticancer therapy, or radiotherapy within 3 months prior to&#xD;
             screening&#xD;
&#xD;
         10. Women of childbearing potential who do not agree to use medically allowed methods of&#xD;
             contraception or to be heterosexually inactive until 60 days after the last dose of&#xD;
             the IP&#xD;
&#xD;
         11. Pregnant or breastfeeding woman&#xD;
&#xD;
         12. Treatment with other IPs within 6 months prior to participation in this study&#xD;
&#xD;
         13. Other reasons including medical reasons based on which the individual is considered to&#xD;
             be ineligible for this study in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YJ Lee</last_name>
    <phone>+82-2-572-6675</phone>
    <email>yjlee@eubiologics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Eunpyeong St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JH Choi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

